Henlius Begins First-in-Human Trial of First-in-Class B7-H3 Cancer Fusion Protein

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an update.

Shanghai Henlius Biotech has dosed the first patient in a first-in-human phase 1 clinical trial of HLX316, an experimental B7-H3-targeting sialidase Fc fusion protein, in patients with advanced or metastatic solid tumours in mainland China. The study will assess safety, tolerability, pharmacokinetics and preliminary efficacy, using a staged dose-escalation and expansion design to establish the maximum tolerated dose and recommended phase 2 dose.

HLX316 combines Henlius’ proprietary B7-H3-targeting VHH antibody domain with a licensed sialidase fusion technology to desialylate tumour cells, relieve immunosuppression and enhance anti-tumour immune responses, with pre-clinical data indicating potent tumour growth inhibition. With no B7-H3-targeting sialidase Fc fusion protein yet approved globally, the trial underscores Henlius’ push into first-in-class oncology biologics, though clinical success and eventual commercialisation remain uncertain for investors.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company focused on developing innovative biologic therapies, including antibody-based drugs and fusion proteins for oncology. The company targets unmet medical needs in advanced and metastatic cancers, with a pipeline aimed at both domestic Chinese and broader global markets.

Average Trading Volume: 921,479

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$38.67B

Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.